Treatment of severe pemphigus vulgaris with rituximab
DOI:
https://doi.org/10.66344/jpad.v31i1.1709Abstract
Pemphigus vulgaris is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-3 and desmoglein-1 located on keratinocytes. Rituximab, a monoclonal anti-CD20 antibody depleting B-cells, offers an effective treatment possibility for therapy-resistant pemphigus vulgaris. Here, we present a case of 20-year-old female who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, mycophenolate mofetil and intravenous immunoglobulins but underwent almost complete remission after rituximab treatment. It was given as two injections of 500mg each at an interval of two weeks in ICU setting.
References
1. Büsing V, Kern J, S, Bruckner-Tuderman L, Hofmann S, C: Recalcitrant Pemphigus Vulgaris Responding to Systemic Tacrolimus. Dermatology. 2010;221:122-6. doi: 10.1159/000314155
2. Ioannides D, Lazaridou E, Rigopoulos D. Pemphigus. J Eur Acad Dermatol Venereol. 2008;22(12):1478-96. doi: 10.1111/j.1468-3083.2008.02825.x. PMID: 18637862.
3. Mutasim DF. Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol. 2004;51(6):859-77; 878-80.
doi: 10.1016/j.jaad.2004.02.013. PMID: 15583576.
4. Kanwar AJ, Vinay K. Rituximab in pemphigus. Indian J Dermatol Venereol Leprol. 2012;78(6):671-6.
doi: 10.4103/0378-6323.102354. PMID: 23075635.
5. Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D. Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8(1):521–7.
6. Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs. 2014;6(4):820–37. doi:10.4161/mabs.29105.
7. Schmidt, E., Hunzelmann, N., Zillikens, D., Brocker, E.-B., & Goebeler, M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31(4):503–8. https://doi.org/10.1111/j.1365-2230.2006.02151.
8. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29(3):405-14. doi:10.1111/jdv.12772.
9. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux3): A prospective, multicentre, parallel-group, open-label randomised trial. Lancet Lond Engl 2017;389:2031-40.
10. Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: Recommendations by an international panel of experts. J Am Acad Dermato.l 2018. pii: S0190-9622(18)30207-X. doi: 10.1016/j.jaad.2018.02.021.
11. Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14:323–31. 10.1016/j.autrev.2014.12.002.
12. Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009;1173:683-91.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Fatima Bashir, Aitisam Waheed, Madiha Sanai, Ahmad Kazmi, Aneela Asghar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
